| Literature DB >> 27838642 |
Gloria Adjapong1, Marie Hale1, Ashley Garrill1.
Abstract
Vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC) affect millions of women and are typically treated with azoles. We know little about azole susceptibility of Candida species from VVC versus RVVC patients, and nothing about African isolates. We have investigated the susceptibility of Candida isolates from Ghana to fluconazole, itraconazole and/or voriconazole. The percentage of Candida albicans isolates showing susceptibility was significantly lower in RVVC than VVC patients. Isolates of Candida parapsilosis and Candida tropicalis showed a similar trend. For Candida glabrata there was no observed difference. The data indicate a decreased susceptibility in selected Candida species from RVVC patients.Entities:
Keywords: Candida; Ghana; azole susceptibility; recurrent vulvovaginal candidiasis; vulvovaginal candidiasis
Mesh:
Substances:
Year: 2017 PMID: 27838642 DOI: 10.1093/mmy/myw122
Source DB: PubMed Journal: Med Mycol ISSN: 1369-3786 Impact factor: 4.076